Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Endothelin-1 (8-21), Succinyl-(glu(9),ala(11,15))-
2. Irl 1620
3. Irl-1620
4. Spi-1620
5. Succinyl-(glu(9),ala(11,15))-endothelin-1 (8-21)
6. Succinyl-(glutamyl(9)-alanyl(11,15))-endothelin-1 (8-21)
1. Spi-1620
2. Deeavyfahldiiw
3. C86h117n17o27
4. Suc[glu9,ala11,15]et-110-21
5. (asp-1 = Suc-asp)
6. Spi 1620
7. Gtpl3886
8. Chembl3188091
9. Irl1620
10. Irl2620
11. Mfcd00214284
12. Akos024456459
13. Suc-asp-glu-glu-ala-val-tyr-phe-ala-his-leu-asp-ile-ile-trp-oh
14. Succinyl-(glu9,ala11 Inverted Exclamation Mark Currency15)-endothelin-1 (8-21)
15. Succinyl-(glu9,ala11?15)-endothelin-1 (8-21) (suc-asp-glu-glu-ala-val-tyr-phe-ala-his-leu-asp-ile-ile-trp)
| Molecular Weight | 1820.9 g/mol |
|---|---|
| Molecular Formula | C86H117N17O27 |
| XLogP3 | 2.1 |
| Hydrogen Bond Donor Count | 23 |
| Hydrogen Bond Acceptor Count | 28 |
| Rotatable Bond Count | 56 |
| Exact Mass | 1819.83048152 g/mol |
| Monoisotopic Mass | 1819.83048152 g/mol |
| Topological Polar Surface Area | 696 Ų |
| Heavy Atom Count | 130 |
| Formal Charge | 0 |
| Complexity | 3920 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 16 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
The new funding will provide Pharmazz to complete the U.S. Phase 3 clinical trial of Tycamzzi (sovateltide), its lead drug candidate for treating acute cerebral ischemic stroke.
Lead Product(s): Sovateltide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tycamzzi
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 11, 2025
Lead Product(s) : Sovateltide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : $25.0 million
Deal Type : Financing
Pharmazz Gets $25M Strategic Equity Investment from Sun Pharma
Details : The new funding will provide Pharmazz to complete the U.S. Phase 3 clinical trial of Tycamzzi (sovateltide), its lead drug candidate for treating acute cerebral ischemic stroke.
Product Name : Tycamzzi
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
June 11, 2025
Details:
The financing will support completion of Pharmazz's pivotal Phase 3 study for Tyvalzi (sovateltide) to treat patients with acute cerebral ischemic stroke.
Lead Product(s): Sovateltide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 21, 2024
Lead Product(s) : Sovateltide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : $15.0 million
Deal Type : Financing
Pharmazz and Sun Pharma Partner for $15 Million Investment in Pharmazz
Details : The financing will support completion of Pharmazz's pivotal Phase 3 study for Tyvalzi (sovateltide) to treat patients with acute cerebral ischemic stroke.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
August 21, 2024
Details:
Tycamzzi (Sovateltide), is a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, which is investigated for the treatment of acute cerebral ischemic stroke patients.
Lead Product(s): Sovateltide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 02, 2023
Lead Product(s) : Sovateltide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tycamzzi (Sovateltide), is a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, which is investigated for the treatment of acute cerebral ischemic stroke patients.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 02, 2023
Details:
Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.
Lead Product(s): Sovateltide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2023
Lead Product(s) : Sovateltide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Pharmazz Inc. and Sun Pharma Enter into Licensing Agreement for Introducing Tyvalzi™ (sovateltid...
Details : Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
September 13, 2023
Details:
Sovateltide is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Brain Ischemia.
Lead Product(s): Sovateltide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 21, 2023
Lead Product(s) : Sovateltide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sovateltide is a Peptide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Brain Ischemia.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 21, 2023
Details:
Tycamzzi, a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, receives marketing approval in India for the treatment of acute cerebral ischemic stroke. Sovateltide is in Phase 3 trial in US for the same indication.
Lead Product(s): Sovateltide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 31, 2023
Lead Product(s) : Sovateltide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tycamzzi, a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, receives marketing approval in India for the treatment of acute cerebral ischemic stroke. Sovateltide is in Phase 3 trial in US for the sa...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
May 31, 2023
Details:
Tycamzzi (sovateltide) is a highly selective endothelin-B receptor agonist, having the potential to be a neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in acute cerebral ischemic stroke patients.
Lead Product(s): Sovateltide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 13, 2023
Lead Product(s) : Sovateltide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tycamzzi (sovateltide) is a highly selective endothelin-B receptor agonist, having the potential to be a neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in acute cerebral ische...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
February 13, 2023
Details:
Results of this trial shows highly encouraged regarding the potential of Tycamzzi (sovateltide) to be the first therapeutic since tPA to demonstrate a positive impact on patients suffering from acute ischemic stroke.
Lead Product(s): Sovateltide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 10, 2023
Lead Product(s) : Sovateltide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results of this trial shows highly encouraged regarding the potential of Tycamzzi (sovateltide) to be the first therapeutic since tPA to demonstrate a positive impact on patients suffering from acute ischemic stroke.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
February 10, 2023
Details:
Sovateltide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ischemic Stroke.
Lead Product(s): Sovateltide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 19, 2023
Lead Product(s) : Sovateltide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Details : Sovateltide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ischemic Stroke.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 19, 2023
Details:
PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Lead Product(s): Sovateltide,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 31, 2022
Lead Product(s) : Sovateltide,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s ...
Details : PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke pa...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 31, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
70
PharmaCompass offers a list of Sovateltide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sovateltide manufacturer or Sovateltide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sovateltide manufacturer or Sovateltide supplier.
PharmaCompass also assists you with knowing the Sovateltide API Price utilized in the formulation of products. Sovateltide API Price is not always fixed or binding as the Sovateltide Price is obtained through a variety of data sources. The Sovateltide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sovateltide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sovateltide, including repackagers and relabelers. The FDA regulates Sovateltide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sovateltide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sovateltide supplier is an individual or a company that provides Sovateltide active pharmaceutical ingredient (API) or Sovateltide finished formulations upon request. The Sovateltide suppliers may include Sovateltide API manufacturers, exporters, distributors and traders.
Sovateltide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sovateltide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sovateltide GMP manufacturer or Sovateltide GMP API supplier for your needs.
A Sovateltide CoA (Certificate of Analysis) is a formal document that attests to Sovateltide's compliance with Sovateltide specifications and serves as a tool for batch-level quality control.
Sovateltide CoA mostly includes findings from lab analyses of a specific batch. For each Sovateltide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sovateltide may be tested according to a variety of international standards, such as European Pharmacopoeia (Sovateltide EP), Sovateltide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sovateltide USP).
